Allogeneic CD-19 CAR-T Cell Therapy

N/A

Report date: 2024/11/25 20:00:28

Base Information

Drug NameAllogeneic CD-19 CAR-T Cell Therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesShenzhen University General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShenzhen University General Hospital

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia

Other Information

ATC CodeN/A